MCM
MYOV

Marathon Capital Management’s Myovant Sciences Ltd. MYOV Stock Holding History

Marathon Capital Management’s Portfolio MYOV Stock Details MYOV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-12,330
Closed -$277K – 230
2021
Q3 		$277K Hold
12,330
– – 0.06% 175
2021
Q2 		$280K Buy
12,330
+1,757
+17% +$37K 0.06% 144
2021
Q1 		$217K Buy
+10,573
New +$241K 0.06% 171

Other funds holding MYOV

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Marathon Capital Management's MYOV Position: Q4 2021 in Review

Marathon Capital Management sold out of Myovant Sciences Ltd. (MYOV) in Q4 2021, closing a stake of 12,330 shares — an estimated $277K sold.

Marathon Capital Management first reported a position in MYOV in Q1 2021 and held it in 3 quarters. The position peaked at $280K in Q2 2021. 110 funds tracked by Wall St. Rank hold MYOV as of Q4 2021.

  • Marathon Capital Management reported no remaining Myovant Sciences Ltd. position as of Q4 2021 after selling out during the quarter.
  • Marathon Capital Management sold 12,330 Myovant Sciences Ltd. shares in Q4 2021, an estimated $277K.
  • Marathon Capital Management first reported a position in Myovant Sciences Ltd. in Q1 2021 and held it in 3 quarters.
  • Marathon Capital Management's Myovant Sciences Ltd. position peaked at $280K in Q2 2021.
  • 110 funds tracked by Wall St. Rank held Myovant Sciences Ltd. as of Q4 2021.

Based on Marathon Capital Management's 13F filing for Q4 2021, filed 9 Feb 2022.